These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 18260885)

  • 21. The cost-effectiveness analysis of JinQi Jiangtang tablets for the treatment on prediabetes: a randomized, double-blind, placebo-controlled, multicenter design.
    Sun X; Guo L; Shang H; Ren M; Wang Y; Huo D; Lei X; Wang H; Zhai J
    Trials; 2015 Nov; 16():496. PubMed ID: 26530718
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic syndrome and its single traits as risk factors for diabetes in people with impaired glucose tolerance: the STOP-NIDDM trial.
    Hanefeld M; Karasik A; Koehler C; Westermeier T; Chiasson JL
    Diab Vasc Dis Res; 2009 Jan; 6(1):32-7. PubMed ID: 19156626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of Insulin Resistance and β-Cell Dysfunction Between the Young and the Elderly in Normal Glucose Tolerance and Prediabetes Population: A Prospective Study.
    Chen G; Shi L; Cai L; Lin W; Huang H; Liang J; Li L; Lin L; Tang K; Chen L; Lu J; Bi Y; Wang W; Ning G; Wen J
    Horm Metab Res; 2017 Feb; 49(2):135-141. PubMed ID: 27459384
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early insulin treatment to prevent cardiovascular disease in prediabetes and overt diabetes.
    Roman G; Hancu N
    Horm Metab Res; 2009 Feb; 41(2):116-22. PubMed ID: 19214921
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impaired glucose tolerance and impaired fasting glucose--a review of diagnosis, clinical implications and management.
    Petersen JL; McGuire DK
    Diab Vasc Dis Res; 2005 Feb; 2(1):9-15. PubMed ID: 16305067
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin.
    Chazova I; Almazov VA; Shlyakhto E
    Diabetes Obes Metab; 2006 Jul; 8(4):456-65. PubMed ID: 16776753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reflecting on type 2 diabetes prevention: more questions than answers!
    Rosenstock J
    Diabetes Obes Metab; 2007 Sep; 9 Suppl 1():3-11. PubMed ID: 17877541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
    Krum H; McMurray JJ; Horton E; Gerlock T; Holzhauer B; Zuurman L; Haffner SM; Bethel MA; Holman RR; Califf RM
    Cardiovasc Ther; 2010 Apr; 28(2):124-32. PubMed ID: 20184589
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of type 2 diabetes with combined therapy: what are the pros and cons?
    Massi-Benedetti M; Orsini-Federici M
    Diabetes Care; 2008 Feb; 31 Suppl 2():S131-5. PubMed ID: 18227473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dose-related antihyperglycemic and hypolipidemic effects of two novel thiazolidin-4-ones in a rodent model of metabolic syndrome.
    Karot SS; Surenahalli VG; Kishore A; Mudgal J; Nandakumar K; Chirayil MT; Mathew G; Nampurath GK
    J Diabetes; 2016 Sep; 8(5):629-39. PubMed ID: 26345135
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rationale and design of a clinical trial to evaluate metformin and colesevelam HCl as first-line therapy in type 2 diabetes and colesevelam HCl in prediabetes.
    Jones MR; Mudaliar S; Hernandez-Triana E; Unnikrishnan AG; Lai YL; Abby SL; Misir S; Jin X; Nagendran S
    Curr Med Res Opin; 2009 Sep; 25(9):2239-49. PubMed ID: 19622007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Should the metabolic syndrome patient with prediabetes be offered pharmacotherapy?
    Sullivan SD; Ratner RE
    Curr Diab Rep; 2011 Apr; 11(2):91-8. PubMed ID: 21207204
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synergistic effects of acarbose and an Oroxylum indicum seed extract in streptozotocin and high-fat-diet induced prediabetic mice.
    Sun W; Sang Y; Zhang B; Yu X; Xu Q; Xiu Z; Dong Y
    Biomed Pharmacother; 2017 Mar; 87():160-170. PubMed ID: 28056420
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preservation of β-cell function: the key to diabetes prevention.
    DeFronzo RA; Abdul-Ghani MA
    J Clin Endocrinol Metab; 2011 Aug; 96(8):2354-66. PubMed ID: 21697254
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acarbose is a promising therapeutic strategy for the treatment of patients with nonalcoholic steatohepatitis (NASH).
    Yamagishi S; Nakamura K; Inoue H
    Med Hypotheses; 2005; 65(2):377-9. PubMed ID: 15922116
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes.
    Zeymer U
    Int J Cardiol; 2006 Feb; 107(1):11-20. PubMed ID: 16337493
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk factors of diabetes in North Indians with metabolic syndrome.
    Pratyush DD; Tiwari S; Singh S; Singh SK
    Diabetes Metab Syndr; 2016; 10(2 Suppl 1):S68-71. PubMed ID: 26951993
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathophysiology of prediabetes.
    Ferrannini E; Gastaldelli A; Iozzo P
    Med Clin North Am; 2011 Mar; 95(2):327-39, vii-viii. PubMed ID: 21281836
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Anti-diabetic drugs for secondary prevention of cardiovascular disease in mild diabetic and IGT patients: ABC study and PPAR study].
    Asakura M; Kim J; Asanuma H; Kitakaze M
    Nihon Rinsho; 2010 May; 68(5):887-91. PubMed ID: 20446588
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Metabolic syndrome and prediabetic states].
    Galajda P; Mokáň M; Mokáň M
    Vnitr Lek; 2013 Jun; 59(6):453-8. PubMed ID: 23808738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.